
Ocugen, Inc.
HealthcareNASDAQ:OCGN · NASDAQ Capital Market
-$0.01 today
Vol 3.71M · Avg 7.78M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
557.7%
avg 149.5%
ROIC
-278.6%
avg -112.4%
ROA
-155.9%
avg -97.8%
Analysis
ROE is currently the strongest return metric at 557.7% versus its period average of 149.5%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Shankar Musunuri | Co-Founder, Chief Executive Officer & Chairman | $1.26M | — | 62 | $4.96M | 1.46% |
Arun Upadhyay | Chief Scientific Officer and Head of Research & Development | $703,751.00 | — | 44 | $306,197.00 | 0.09% |
Huma Qamar | Chief Medical Officer | $644,027.00 | — | 42 | $1.15M | 0.34% |
Ramesh Ramachandran | Chief Accounting Officer & Principal Accounting Officer | $504,925.00 | — | 58 | $310,950.00 | 0.09% |
Vijay Tammara | Chief Development Officer | $490,915.00 | — | 66 | $42,578.00 | 0.01% |
Uday Kompella | Co-founder & Independent Director | $61,875.00 | — | 59 | $151,316.00 | 0.04% |
Mohamed Genead | Interim Chief Medical Officer | — | — | — | — | — |
Jyothy Pillai | Vice President & Head of Regulatory & Quality | — | — | — | — | — |
Kristen Craft | Head of People & Culture | — | — | — | — | — |
Rita Johnson-Greene | CFO & Principal Accounting Officer | — | — | 49 | $500,000.00 | 0.15% |
Tiffany Hamilton | AVP & Head of Corporate Communications | — | — | — | — | — |
Durgaprasad Annavajjula | Vice President, Head of Program Management & Chief of Staff | — | — | — | — | — |
Paul Staid | Executive Vice President of Operations | — | — | — | — | — |
John Kouch | General Counsel | — | — | — | $25,000.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Alumis Inc. Common Stock
NASDAQ:ALMS
$2.98B
RAPT Therapeutics, Inc.
RAPT
$959.26M

Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$852.86M

Omeros Corporation
NASDAQ:OMER
$632.20M

Neurogene Inc.
NASDAQ:NGNE
$459.84M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$329.81M

Lineage Cell Therapeutics, Inc.
AMEX:LCTX
$316.61M

Compass Therapeutics, Inc.
NASDAQ:CMPX
$280.72M

Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$186.68M

ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
Who manages OCGN?
Ocugen, Inc. (OCGN) lists 14 active executives. The top listed executive is Huma Qamar, Chief Medical Officer.
Are OCGN insiders buying or selling?
Recent insider activity shows net buying of $4.07M.
Explore More
Continue the stock analysis
Jump to another research area for this company.